American Board of Psychiatry and Neurology (ABPN) Practice Exam 2026 - Free ABPN Practice Questions and Study Guide

Sumatriptan, a medication belonging to the triptan class used to treat migraines, is particularly contraindicated in patients with ischemic heart disease. The reason for this contraindication lies in the pharmacological effects of sumatriptan, which can induce vasoconstriction. In patients with ischemic heart disease, where the coronary arteries are already compromised, vasoconstriction may worsen the supply-demand mismatch that can lead to angina, myocardial infarction, or other serious cardiovascular events.

Individuals with ischemic heart disease may experience reduced blood flow to the heart muscle due to narrowed or blocked coronary arteries. The use of sumatriptan could further impair blood flow, increasing the risk of adverse cardiovascular complications. Therefore, it is essential for healthcare providers to avoid prescribing this medication to patients with such a history to ensure their safety and mitigate potential risks.

On the other hand, while kidney disease, obstructive pulmonary disease, and inflammatory bowel disease have considerations in terms of medication effects and overall health, they do not present the same acute risk as ischemic heart disease when it comes to the use of sumatriptan. Each of these conditions might warrant caution or clinical judgment, yet they do not inherently contraindicate the use of sumatriptan